TY - JOUR T1 - Novel genes detected by transcriptional profiling from whole-blood cells in patients with early onset of acute coronary syndrome. JF - Clin Chim Acta Y1 - 2013 A1 - Silbiger, Vivian N A1 - Luchessi, André D A1 - Hirata, Rosário D C A1 - Lima-Neto, Lídio G A1 - Cavichioli, Débora A1 - Carracedo, Ángel A1 - Brión, Maria A1 - Dopazo, Joaquin A1 - Garcia-Garcia, Francisco A1 - Dos Santos, Elizabete S A1 - Ramos, Rui F A1 - Sampaio, Marcelo F A1 - Armaganijan, Dikran A1 - Sousa, Amanda G M R A1 - Hirata, Mario H KW - Acute Coronary Syndrome KW - Acute-Phase Proteins KW - Adult KW - biomarkers KW - Blood Cells KW - Early Diagnosis KW - gene expression KW - Gene Expression Profiling KW - Humans KW - Male KW - Middle Aged KW - Oligonucleotide Array Sequence Analysis KW - RNA, Messenger KW - Transcriptome AB -

BACKGROUND: Genome-wide expression analysis using microarrays has been used as a research strategy to discovery new biomarkers and candidate genes for a number of diseases. We aim to find new biomarkers for the prediction of acute coronary syndrome (ACS) with a differentially expressed mRNA profiling approach using whole genomic expression analysis in a peripheral blood cell model from patients with early ACS.

METHODS AND RESULTS: This study was carried out in two phases. On phase 1 a restricted clinical criteria (ACS-Ph1, n=9 and CG-Ph1, n=6) was used in order to select potential mRNA biomarkers candidates. A subsequent phase 2 study was performed using selected phase 1 markers analyzed by RT-qPCR using a larger and independent casuistic (ACS-Ph2, n=74 and CG-Ph2, n=41). A total of 549 genes were found to be differentially expressed in the first 48 h after the ACS-Ph1. Technical and biological validation further confirmed that ALOX15, AREG, BCL2A1, BCL2L1, CA1, COX7B, ECHDC3, IL18R1, IRS2, KCNE1, MMP9, MYL4 and TREML4, are differentially expressed in both phases of this study.

CONCLUSIONS: Transcriptomic analysis by microarray technology demonstrated differential expression during a 48 h time course suggesting a potential use of some of these genes as biomarkers for very early stages of ACS, as well as for monitoring early cardiac ischemic recovery.

VL - 421 U1 - https://www.ncbi.nlm.nih.gov/pubmed/23535507?dopt=Abstract ER -